Where is Aphios focusing its research in treatments for Alzheimer’s?
Our research on Alzheimer’s disease focuses on mitigating neuroinflammation – a key driver of disease progression. In aging brains, the CCR5 gene becomes increasingly active, contributing significantly to inflammation that disrupts synaptic connectivity and accelerates cognitive decline. Evidence from the HIV field, where individuals lacking CCR5 exhibit resistance to infection, underscores the receptor’s role in immune modulation.
We are repurposing Maraviroc – a molecule used in HIV treatment to block CCR5 – by encapsulating it in nanoparticles. This formulation enables effective crossing of the blood-brain barrier, reducing neuroinflammation while potentially lessening the side effects seen with current anti-amyloid therapies, such as brain bleeding. By blocking CCR5, our strategy aims to preserve synaptic function and slow the progression of Alzheimer’s disease.
How do nanoparticles assist in drug delivery for central nervous system (CNS) disorders?
Nanoparticles offer a promising means to traverse the blood-brain barrier due to their lipid-based composition, which is very biosimilar to this barrier. Once inside, the nanoparticle can deliver its therapeutic cargo directly to the brain. That is a passive transport mechanism.
We are also looking at an active targeting mechanism, in which we enhance delivery by attaching ligands – such as sugar moieties – to the nanoparticle surface. There are many receptors for sugar on the blood-brain barrier, as the brain demands a lot of sugar, so these ligands help transport the nanoparticle material across the blood-brain barrier.
How does Aphios differentiate its nanoparticle formulation process?
Aphios stands out with an innovative approach to making its nanoparticles. Through double-encapsulation – that is, encapsulating the mRNA first within lipid nanoparticles and then within biodegradable polymer shells – we help the drug last longer in the body, and reduced the need for frequent dosing.
Additionally, instead of using traditional methods that require toxic organic solvents, we use supercritical fluids – essentially compressed carbon dioxide, or other gases – to create our particles. This process avoids use of harmful chemicals, resulting in uniform, stable, and safe nanoparticles.
Our supercritical fluid (SuperFluids) acts like a solvent that dissolves lipids effectively. When the pressure is released, the lipids form tiny, consistent nanoparticles. This cleaner process not only produces high-quality particles but also removes the need to rely on oil and gas for organic solvents, for a more environmentally sustainable method of drug production.
How is Aphios exploring cannabinoids for treatment of CNS disorders?
We are investigating use of cannabinoids to rebalance the endocannabinoid system. Cannabis contains over 100 cannabinoids, each exhibiting unique biological activities. Many of these compounds have a short duration of action, limiting their utility for chronic conditions.
Our strategy involves selecting specific cannabinoids – such as CBD – and encapsulating them in nanoparticles to extend their time in the body. This sustained-release approach aims to convert an acute treatment into one suitable for chronic use.
Cannabinoids have already been approved for use in epilepsy and multiple sclerosis cases. We are looking to move into chronic applications across pain, addiction and anxiety.
What is your perspective on the use of natural compounds in the pharmaceutical industry?
Humans are fundamentally connected with nature. About 50% of anti-cancer drugs come from plants, showing how valuable nature’s solutions can be for human health.
Although the pharmaceutical industry traditionally favored synthetic compounds for their ease of control and patentability, many effective drugs originate from natural sources. Natural compounds can be inherently compatible with the body’s biological systems, offering better long-term efficacy and fewer side effects.
By leveraging advanced drug delivery technologies – such as nanoparticle encapsulation and supercritical fluid extraction – we can overcome production challenges associated with natural compounds.
Looking ahead, what are Aphios’ plans for 2025?
Our efforts in 2025 will continue building on the advancements made this year. We spun off a company, Aphios Pharma LLC, which will be focusing on the development of cannabis-based, FDA approved drugs for anxiety, pain, addiction and other CNS disorders. We are going to continue working on our Alzheimer’s disease program.
We received a Japanese patent last year for use of our Zindol products with pregnancy-related nausea and vomiting. Zindol DS will also help with the nauseating side-effects of the new anti-obesity drugs. We will be focusing on getting more products from that line directly out to market.